Company profile: Cellumen
1.1 - Company Overview
Company description
- Provider of cellular systems biology solutions delivering accurate predictions of drug efficacy and safety to drive Discovery Toxicology and reduce failure rates and development costs. Offers biomarker analysis tools, including for COVID-19 and cardiac issues, cloning, assay kits (ELISA and protein), and cDNA for research.
Products and services
- Assay Kits: Research-grade kits for conducting various assays, including ELISA and protein assays, tailored for research applications in laboratory settings
- Biomarkers: Disease-focused tools for assessing biological markers related to health conditions, including COVID-19 and cardiac issues, supporting condition-specific analyses
- Cellular Systems Biology Solutions: Cellular systems biology–based systems that predict drug efficacy and safety, drive Discovery Toxicology, reduce failure rates, and cut development costs by addressing disease and safety complexity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellumen
Wacker Chemie
HQ: Germany
Website
- Description: Provider of silicone products (emulsions, rubber, silica) for electronics and automotive; polymer solutions for construction, adhesives and coatings; high-purity polysilicon for semiconductor and solar; biotechnology products and services including biopharmaceuticals and food ingredients; plus technical competence centers offering expert advice and product development support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wacker Chemie company profile →
CSL
HQ: United States
Website
- Description: Provider of quality system, risk management, support, and consulting services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CSL company profile →
Agility Clinical
HQ: United States
Website
- Description: Provider of consulting and contract research services for virtual and small biopharma and device companies with lean infrastructure, offering expertise to support programs—particularly in orphan drug development—and help them move forward.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agility Clinical company profile →
Advantage Healthcare
HQ: United States
Website
- Description: Provider of critical analyses and insights to support new product in-/out-licensing across pharmaceuticals, biologics, medical devices, diagnostics, and combination products, offering commercial assessments, benchmarking, thought leader access/input, and plan development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advantage Healthcare company profile →
Trinity Life Sciences
HQ: United States
Website
- Description: Provider of strategic and tactical insights for pharmaceutical and biotech, offering Trinity Infinity for integrated strategy, insights, and analytics; Customer Engagement Solutions; Trinity Real Insights predictive insights integrating market research and real-world data; Brand Insights AI; comprehensive market research; and pricing studies to optimize clinical and commercial decision-making.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trinity Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellumen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellumen
2.2 - Growth funds investing in similar companies to Cellumen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellumen
4.2 - Public trading comparable groups for Cellumen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →